Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels. A randomized controlled trial. Ann Surg 2018: 268: 943-954.

Published: 27th February 2019

Authors: Huang G, Li P-P, Lau WY, Pan Z-Y, Zhao L-H, Wang Z-G et al.


Some 200 patients with hepatitis B were included after curative resection of their liver tumour. After five years, patients on antiviral therapy had improved recurrence-free survival (52 vs 32.3 per cent, P=0.016) and overall survival (64.1 vs 43.7 per cent, P=0.004).

Pubmed Link

Your comments